Inclusion Criteria:

          -  Participant must be ≥18 years of age inclusive, at the time of signing the informed
             consent.

          -  Presence of the putative biomarkers of DDR deficiency in tumor and/or other tissues.

          -  Participants must have histologically confirmed solid tumors .

          -  Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1.

          -  Adequate bone marrow function as assessed by aboratory tests to be conducted within 7
             days before the first dose of study intervention.

          -  Participants must have adequate kidney function, as assessed by the estimated
             glomerular filtration rate (eGFR) > 40 mL/min per 1.73 m*2 within 7 days before the
             first dose of study intervention.

          -  Participants must have adequate liver function as assessed by the following laboratory
             tests to be conducted within 7 days before the first dose of study intervention.

          -  Participants must have adequate coagulation, as assessed by laboratory tests as
             applicable, (to be conducted within 7 days before the first dose of study
             intervention) or on stable anti-coagulation treatment.

          -  Adequate cardiac function per institutional normal measured by echocardiography
             (recommended) or multigated acquisition (MUGA) scan/cardiac MRI per institutional
             guidelines.

          -  Participants must have measurable disease (at least one measurable lesion) as per
             RECIST 1.1, or evaluable disease according to the Prostate Cancer Clinical Trials
             Working Group 3 (PCWG3) classification as applicable. Lesions situated in a previously
             irradiated area are considered measurable if progression has been demonstrated in such
             lesions

        Exclusion Criteria:

          -  Ongoing infections of Common terminology criteria for adverse events (CTCAE) grade ≥2
             not responding to therapy or active clinically serious infections.

          -  Participants with

               -  Known human immunodeficiency virus (HIV)

               -  Active Hepatitis B infection (positive for Hepatitis B surface antigen (HBsAg)/
                  Hepatitis B virus (HBV) DNA).

               -  Active Hepatitis C infection (positive anti-HCV Antibody and quantitative HCV RNA
                  results greater than the lower limits of detection of the assay).

          -  Active autoimmune disease (active defined as having autoimmune disease related
             symptoms and detectable autoantibodies) that has required systemic treatment in the
             past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or
             immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is
             not considered a form of systemic treatment

          -  Diagnosis of immunodeficiency or participant is receiving chronic systemic steroid
             therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form
             of immunosuppressive therapy within 7 days prior to the first dose of study
             intervention. The use of physiologic doses of corticosteroids may be approved after
             consultation with the sponsor.

          -  Pleural effusion or ascites that causes respiratory compromise (CTCAE Grade ≥ 2
             dyspnea).

          -  History of cardiac disease: congestive heart failure New York Heart Association (NYHA)
             class >II, unstable angina (angina symptoms at rest), new-onset angina (within the
             past 6 months before study entry), myocardial infarction within the past 6 months
             before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta
             blockers, calcium channel blockers, and digoxin are permitted)

          -  Uncontrolled arterial hypertension despite optimal medical management (per
             investigator's opinion)

          -  Moderate or severe hepatic impairment, i.e., Child-Pugh class B or C.

          -  History of organ allograft transplantation

          -  Evidence or history of bleeding disorder, i.e., any hemorrhage / bleeding event of
             CTCAE Grade > 2 within 4 weeks before the first dose of study intervention